Zachary J. Roberts named executive vice president of R&D at Allogene

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.

April 19, 2024

Vol.50 No.16

Drugs & Targets

FDA approves Abecma for earlier lines of treatment for MM

FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial (The Cancer Letter, March 22, 2024).

April 05, 2024

Vol.50 No.14

Clinical Roundup

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

A phase I CAR T-cell therapy trial for the treatment of glioblastoma demonstrated promising clinical activity, according to research published in Nature Medicine.

March 15, 2024

Vol.50 No.11

Clinical

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

In a major breakthrough in cellular therapy, FDA has approved the first tumor-infiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have received prior treatment, including with checkpoint inhibitors.

February 23, 2024

Vol.50 No.08

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research

Feb. 16, 2024, is a landmark date in the history of immuno-oncology.

February 23, 2024

Vol.50 No.08

By Matthew Bin Han Ong

Clinical Roundup

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

February 23, 2024

Vol.50 No.08

Zachary J. Roberts named executive vice president of R&D at Allogene

YOU MAY BE INTERESTED IN

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

FDA approves Abecma for earlier lines of treatment for MM

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval

Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Renew today!

Subscriber content

Login